학술논문
Successful lorlatinib rechallenge after severe drug-induced psychosis in ALK-positive metastatic non-small cell lung cancer (NSCLC): a case report
Document Type
Article
Author
Source
JTO Clinical and Research Reports; 20240101, Issue: Preprints
Subject
Language
ISSN
26663643
Abstract
Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system (CNS)-active ALK-inhibitor.(1) Manifestations may include psychotic, mood, speech and cognitive symptoms. Current guidance recommends permanent discontinuation of lorlatinib in cases of Grade 4 NAEs.